Experienced in Teratoma of the Mediastinum

Hao Y. Zeng

No. 105, Jiuyi North Road, 
Longyan, CN 
Experienced in Teratoma of the Mediastinum
No. 105, Jiuyi North Road, 
Longyan, CN 
OverviewLocationsClinical Research

Overview

Hao Zeng practices in Longyan, China. Mr. Zeng is rated as an Experienced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Methicillin-Resistant Staphylococcus Aureus (MRSA), Prostatectomy, and Nephrectomy.

His clinical research consists of co-authoring 512 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

No. 105, Jiuyi North Road, Longyan, 364000, China
Other Locations
State Key Laboratory Of Materials Oriented Chemical Engineering, Nanjing, 211816, China
639 Longmian Avenue, Nanjing, 211198, China
The 30th, Gaotanyan Street, Tanjiagang, 400038, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3

512 Total Publications

O-GlcNAc transferase promotes immune evasion and immunotherapy resistance in uterine corpus endometrial cancer by targeting the glucocorticoid receptor.
O-GlcNAc transferase promotes immune evasion and immunotherapy resistance in uterine corpus endometrial cancer by targeting the glucocorticoid receptor.
Journal: Journal for immunotherapy of cancer
Published: September 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Zeng's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 64 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile